Exelixis | EXEL - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Acadia Pharmaceuticals USD 3.98M 22.34M 2026-03
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Akebia Therapeutics USD -11.24M 12.39M 2025-12
Amgen USD 1.51B 2.41B 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
Bayer EUR -3.37B 2.21B 2025-12
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Cytokinetics USD -206.03M 23M 2026-03
Eisai JPY -7.94B 29.94B 2026-03
Eli Lilly USD 8.27B 1.03B 2025-12
Exelixis USD 267.69M 15M 2026-03
Genmab DKK 55M 427M 2025-12
Glaxosmithkline GBP 2.14B 312M 2026-03
Incyte USD 343.6M 46.34M 2026-03
Ionis Pharmaceuticals USD -93M 135M 2026-03
MacroGenics USD -36.77M 21.84M 2026-03
Merck USD 3.42B 3.32B 2025-12
Moderna USD -799M 612M 2025-12
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novartis USD 3.84B 802M 2026-03
Pfizer USD 5.18B 6.82B 2026-03
Puma Biotechnology USD 20.61M 24.76M 2024-09
Sanofi EUR 2B 3.16B 2026-03
Takeda JPY -52.48B 186.34B 2026-03
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
Xencor USD -128.64M 124.37M 2026-03